GEN Exclusives

More »

GEN News Highlights

More »
Apr 6, 2012

American CryoStem, PGen to Develop Stem Cells for Wound Healing

  • American CryoStem and Protein Genomics (PGen) have agreed to work together to develop cellular therapies for the wound healing and other regenerative markets. The companies will initially focus their efforts toward creating applications for injuries and conditions that are difficult to treat, such as chronic, acute, and traumatic wounds.

    American CryoStem will contribute certain intellectual property, know-how, and trade secrets, including clinically prepared adipose-derived stem cells using the company's tissue processing products and stromal cell culture media. PGen will contribute certain know-how and trade secrets as well as patented Elastatropin® human-based protein.

    Elastatropin, or human tropoelastin, is an over-the-counter product for wound closure applications. Tropoelastin is a precursor to elastin, a molecule in the extracellular matrix that, in particular, provides strength and elasticity of skin. PGen’s development and production of human tropoelastin for wound healing has resulted in new discoveries that permit additional uses.

    American CryoStem markets clinical processing services and patented products for adipose tissue and adipose-derived adult stem cells. The firm provides clinical processing, patented cell culture media products, and a cellular preservation platform.

    “Discussions have been under way for some time, and this formalized collaborative agreement is phase one of combining these two unique patented technologies,” says John Arnone, CEO of American CryoStem. “This collaboration is part of the company's efforts to leverage its clinical laboratory processes into the cellular therapy and regenerative medicine application market.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?